Cite
HARVARD Citation
Emery, P. et al. (2017). Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study. Annals of the rheumatic diseases. 76 (1), pp. 96-104. [Online].